EBMT 2017

4:58
Concerns about using social media in oncology
Naveen Pemmaraju
1:47
Predicting and preventing clonal evolution in multiple myeloma
Irene Ghobrial
1:24
Only the beginning of precision medicine and multiple myeloma.
Irene Ghobrial
4:01
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Sebastian Giebel
1:24
Treatment methods in mantle cell lymphoma
Stephen Robinson
2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson
2:00
Updates on treatment methods for Hodgkin Lymphoma
Stephen Robinson
1:26
Cellular therapy: a key part of EBMT 2017
Nicolaus Kröger
3:14
Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome
Maria Teresa Voso
3:26
What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau
6:43
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister
2:36
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben
2:40
Can the cytomegalovirus be predicted by ELISpot assays?
Roy Chemaly
2:19
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon
1:50
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial
3:44
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals